Literature DB >> 33649568

Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells.

Kenji Sugata1, Yukiko Matsunaga1, Yuki Yamashita1, Munehide Nakatsugawa1, Tingxi Guo1, Levon Halabelian2, Yota Ohashi1,3, Kayoko Saso1, Muhammed A Rahman1, Mark Anczurowski1,3, Chung-Hsi Wang1,3, Kenji Murata1, Hiroshi Saijo1, Yuki Kagoya1, Dalam Ly1, Brian D Burt1, Marcus O Butler1,3,4, Tak W Mak1,3, Naoto Hirano5,6.   

Abstract

Peptide-major histocompatibility complex (pMHC) multimers enable the detection of antigen-specific T cells in studies ranging from vaccine efficacy to cancer immunotherapy. However, this technology is unreliable when applied to pMHC class II for the detection of CD4+ T cells. Here, using a combination of molecular biological and immunological techniques, we cloned sequences encoding human leukocyte antigen (HLA)-DP, HLA-DQ and HLA-DR molecules with enhanced CD4 binding affinity (with a Kd of 8.9 ± 1.1 µM between CD4 and affinity-matured HLA-DP4) and produced affinity-matured class II dimers that stain antigen-specific T cells better than conventional multimers in both in vitro and ex vivo analyses. Using a comprehensive library of dimers for HLA-DP4, which is the most frequent HLA allele in many ancestry groups, we mapped 103 HLA-DP4-restricted epitopes derived from diverse tumor-associated antigens and cloned the cognate T-cell antigen receptor (TCR) genes from in vitro-stimulated CD4+ T cells. The availability of affinity-matured class II dimers across HLA-DP, HLA-DQ and HLA-DR alleles will aid in the investigation of human CD4+ T-cell responses.
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Year:  2021        PMID: 33649568     DOI: 10.1038/s41587-021-00836-4

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  53 in total

1.  T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics.

Authors:  J R Wyer; B E Willcox; G F Gao; U C Gerth; S J Davis; J I Bell; P A van der Merwe; B K Jakobsen
Journal:  Immunity       Date:  1999-02       Impact factor: 31.745

Review 2.  The nature of molecular recognition by T cells.

Authors:  Simon J Davis; Shinji Ikemizu; Edward J Evans; Lars Fugger; Talitha R Bakker; P Anton van der Merwe
Journal:  Nat Immunol       Date:  2003-03       Impact factor: 25.606

Review 3.  Class II major histocompatibility complex tetramer staining: progress, problems, and prospects.

Authors:  Sabrina S Vollers; Lawrence J Stern
Journal:  Immunology       Date:  2008-03       Impact factor: 7.397

Review 4.  Similarities and differences in CD4+ and CD8+ effector and memory T cell generation.

Authors:  Robert A Seder; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-09       Impact factor: 25.606

Review 5.  MHC class II tetramers.

Authors:  Gerald T Nepom
Journal:  J Immunol       Date:  2012-03-15       Impact factor: 5.422

6.  T Cell Receptor Binding to a pMHCII Ligand Is Kinetically Distinct from and Independent of CD4.

Authors:  Y Xiong; P Kern; H Chang; E Reinherz
Journal:  J Biol Chem       Date:  2000-12-05       Impact factor: 5.157

7.  Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers.

Authors:  A L Meyer; C Trollmo; F Crawford; P Marrack; A C Steere; B T Huber; J Kappler; D A Hafler
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

8.  CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes.

Authors:  K C Garcia; C A Scott; A Brunmark; F R Carbone; P A Peterson; I A Wilson; L Teyton
Journal:  Nature       Date:  1996-12-12       Impact factor: 49.962

9.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

10.  Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions.

Authors:  Peter Jönsson; Jennifer H Southcombe; Ana Mafalda Santos; Jiandong Huo; Ricardo A Fernandes; James McColl; Melissa Lever; Edward J Evans; Alexander Hudson; Veronica T Chang; Tomáš Hanke; Andrew Godkin; Paul D Dunne; Mathew H Horrocks; Matthieu Palayret; Gavin R Screaton; Jan Petersen; Jamie Rossjohn; Lars Fugger; Omer Dushek; Xiao-Ning Xu; Simon J Davis; David Klenerman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-25       Impact factor: 11.205

View more
  6 in total

1.  HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma.

Authors:  Benjy Jy Tan; Kenji Sugata; Omnia Reda; Misaki Matsuo; Kyosuke Uchiyama; Paola Miyazato; Vincent Hahaut; Makoto Yamagishi; Kaoru Uchimaru; Yutaka Suzuki; Takamasa Ueno; Hitoshi Suzushima; Hiroo Katsuya; Masahito Tokunaga; Yoshikazu Uchiyama; Hideaki Nakamura; Eisaburo Sueoka; Atae Utsunomiya; Masahiro Ono; Yorifumi Satou
Journal:  J Clin Invest       Date:  2021-12-15       Impact factor: 19.456

Review 2.  Recent advances in cancer immunotherapy.

Authors:  Qiang Sun; Gerry Melino; Ivano Amelio; Jingting Jiang; Ying Wang; Yufang Shi
Journal:  Discov Oncol       Date:  2021-08-18

3.  MYC inhibition, courtesy of E. coli.

Authors:  Karen O'Leary
Journal:  Nat Rev Cancer       Date:  2021-04       Impact factor: 60.716

4.  In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles.

Authors:  Fang-Yi Su; Qingyang Henry Zhao; Shreyas N Dahotre; Lena Gamboa; Swapnil Subhash Bawage; Aaron D Silva Trenkle; Ali Zamat; Hathaichanok Phuengkham; Rafi Ahmed; Philip J Santangelo; Gabriel A Kwong
Journal:  Sci Adv       Date:  2022-02-23       Impact factor: 14.957

5.  Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy.

Authors:  Ariel Isser; Aliyah B Silver; Hawley C Pruitt; Michal Mass; Emma H Elias; Gohta Aihara; Si-Sim Kang; Niklas Bachmann; Ying-Yu Chen; Elissa K Leonard; Joan G Bieler; Worarat Chaisawangwong; Joseph Choy; Sydney R Shannon; Sharon Gerecht; Jeffrey S Weber; Jamie B Spangler; Jonathan P Schneck
Journal:  Nat Commun       Date:  2022-10-14       Impact factor: 17.694

Review 6.  Mechanistic and Biomarker Studies to Demonstrate Immune Tolerance in Multiple Sclerosis.

Authors:  María José Docampo; Andreas Lutterotti; Mireia Sospedra; Roland Martin
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.